(December 2, 2015) Research funded in part by an OCRF grant to Rachel Grisham, MD has identified new, potentially targetable mutations in patients with low grade serous ovarian cancer. Dr. Grisham is a medical oncologist at Memorial Sloan Kettering Cancer Center in New York and is a 2014 recipient of the Liz Tilberis Early Career … Continued
(December 1, 2015) Research funded in part by Ovarian Cancer Research Fund, and published in PNAS, offers new insights into how ovarian cancer grows—and the potential to stop it. Can any cancer cell form another tumor, or is it only select cancer stem cells that give rise to new cancer cells? The answer, a new … Continued
(November 20, 2015) A study published in BMC Cancer demonstrates that ovarian cancer patients who had a history of oral contraceptive use had better outcomes than those who had not previously used them. Dr. Aminah Jatoi and co-author Dr. Ellen Goode, both of the Mayo Clinic, examined 1,398 cases during a thirteen year period and … Continued
(Nov. 19, 2016) In research published this month in Gynecologic Oncology, a group of Canadian researchers have found that long-term survival is not associated with BRCA mutation status in ovarian cancer patients. Past research has shown that after a diagnosis of ovarian cancer, positive BRCA mutation status confers a mortality benefit that diminishes with time. In … Continued
November 18, 2015 Contact: Lisa Mauti lmauti@ovariancancer.org Public health evidence points to need for FDA regulation of laboratory developed tests “The consequences of inaccurate test results, such as false positives, can result in the unnecessary removal of a woman’s ovaries. It is critical that patients know their test results can be trusted.” Washington, DC — … Continued
Washington, DC — On November 17th, the Food and Drug Administration (FDA) released a report: The Public Health Evidence for FDA Oversight of Laboratory Developed Tests: 20 Case Studies, that outlines the harm that not regulating laboratory developed tests (LDTs) can cause to patients and to the economy. Included in the report were two case studies about … Continued
OCRF has awarded $5.2 million in new grants, bringing our total investment in ovarian cancer research to nearly $70 million.
A new study of ovarian cancer cells from the University of Michigan Comprehensive Cancer Center, funded in part by an OCRF grant to Dr. Weiping Zou, reveals molecular changes within the tumor that prevent immunotherapy drugs from killing off the cancer. The research was published in Nature. Immunotherapy treatments have proven wildly successful in treating … Continued
Earlier this month, we attended the AACR conference Advances in Ovarian Cancer Research: Exploiting Vulnerabilities, which highlighted many recent pre-clinical advancements in the treatment of ovarian cancer. Much of the work presented was hot off the presses and unpublished – so we were asked not to share too many details from the work publicly. To … Continued
For Immediate ReleaseSeptember 23, 2015 New Ovarian Cancer National Alliance research finds state lawmakers have power to dramatically improve access to ovarian cancer care and outcomes for the 21,000 women diagnosed each year WASHINGTON, D.C. — Today, the Ovarian Cancer National Alliance (OCNA) released groundbreaking new data in its report “50 States of Teal: Ovarian … Continued
For Immediate ReleaseSeptember 28, 2015 Representatives Sean Duffy (R-WI) and Rosa DeLauro (D-CT) to launch Congressional Ovarian Cancer Caucus at Rally on Tuesday Representatives Sean Duffy (R-WI) and Rosa DeLauro (D-CT) to launch Congressional Ovarian Cancer Caucus at Rally on Tuesday WASHINGTON, D.C. — Tomorrow, Representatives Sean Duffy and Rosa DeLauro, who have each been … Continued
Missed a day during #30DaysofTeal? Click the plus sign to see everything we did during the month of September!
Get email updates about research news, action alerts, and ways to join the fight.
